FAQ on Clene's NIH-Funded Program for CNM-Au8® in ALS

What is CNM-Au8® and what is its purpose?

CNM-Au8® is an investigational first-in-class therapy by Clene Nanomedicine Inc. aimed at improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases like ALS, Parkinson’s disease, and multiple sclerosis.

Why is the NIH funding the Expanded Access Program for CNM-Au8® in ALS?

The NIH is funding this program to support broader access to CNM-Au8® for ALS patients outside clinical trials, recognizing its potential to lower the risk of death and delay clinical worsening based on Phase 2 clinical studies.

How does CNM-Au8® work?

CNM-Au8® targets mitochondrial function and the NAD pathway to improve central nervous system cells’ survival and function while reducing oxidative stress.

Who is involved in the Expanded Access Program for CNM-Au8®?

Clene Inc., its subsidiary Clene Nanomedicine Inc., Columbia University, and Synapticure are collaborating on this program, with funding from the National Institute of Neurological Disorders and Stroke (NINDS), part of the NIH.

When was the NIH grant for this program announced?

The four-year grant from the NINDS was announced late last year, supporting the Expanded Access Program for CNM-Au8® in ALS.

Where can I find more information about Clene and CNM-Au8®?

For more information, visit Clene’s official website at www.Clene.com or the full press release at https://ibn.fm/qrhL5.

What are the implications of this program for ALS patients?

This program provides ALS patients with access to CNM-Au8® outside of clinical trials, offering a potential treatment option that has shown to be well-tolerated and associated with positive outcomes in early studies.

How can ALS patients participate in the Expanded Access Program?

The content does not specify participation details, but interested individuals are encouraged to contact Clene Inc. or visit their website for more information.

What makes CNM-Au8® different from other ALS treatments?

CNM-Au8® is unique as it focuses on improving mitochondrial health and neuronal function through a novel mechanism, distinguishing it from other ALS treatments that may target different pathways or symptoms.